Latest news
Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 11:39:25 GMTFDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1 - Managed Healthcare ExecutiveManaged Healthcare Executive · Fri, 07 Aug 2026 20:06:51 GMTFDA Approves First-in-Class Narcolepsy Drug - LabrootsLabroots · Fri, 07 Aug 2026 16:07:00 GMTFDA approves Takeda’s first-in-class narcolepsy drug - EMJEMJ · Fri, 07 Aug 2026 15:12:52 GMTFDA approves Orzeyful for narcolepsy type 1 in adults - aasm.orgaasm.org · Fri, 07 Aug 2026 14:23:12 GMTFierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 12:35:10 GMTTakeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 09:53:37 GMTTakeda (TAK) Wins FDA Approval For First-In-Class Narcolepsy Drug Orzeyful With $2–3 Billion Peak Sales Target - londoninsider.co.uklondoninsider.co.uk · Fri, 07 Aug 2026 05:51:01 GMT